Literature DB >> 27849169

Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.

Marie-Louise Sentman1, Joana M Murad2, W James Cook1, Ming-Ru Wu1, Jake Reder2, Susanne H Baumeister3,4,5,6, Glenn Dranoff3,7, Michael W Fanger2, Charles L Sentman8.   

Abstract

Targeting cancer through the use of effector T cells bearing chimeric Ag receptors (CARs) leads to elimination of tumors in animals and patients, but recognition of normal cells or excessive activation can result in significant toxicity and even death. CAR T cells based on modified NKG2D receptors are effective against many types of tumors, and their efficacy is mediated through direct cytotoxicity and cytokine production. Under certain conditions, their ligands can be expressed on nontumor cells, so a better understanding of the potential off-tumor activity of these NKG2D CAR T cells is needed. Injection of very high numbers of activated T cells expressing CARs based on murine NKG2D or DNAM1 resulted in increased serum cytokines (IFN-γ, IL-6, and MCP-1) and acute toxicity similar to cytokine release syndrome. Acute toxicity required two key effector molecules in CAR T cells-perforin and GM-CSF. Host immune cells also contributed to this toxicity, and mice with severe immune cell defects remained healthy at the highest CAR T cell dose. These data demonstrate that specific CAR T cell effector mechanisms and the host immune system are required for this cytokine release-like syndrome in murine models.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27849169      PMCID: PMC5136298          DOI: 10.4049/jimmunol.1600769

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.

Authors:  Elke Pogge von Strandmann; Hinrich P Hansen; Katrin S Reiners; Roland Schnell; Peter Borchmann; Sabine Merkert; Venkateswara R Simhadri; Andreas Draube; Marcel Reiser; Ingvill Purr; Michael Hallek; Andreas Engert
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

4.  Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Authors:  Duck Cho; David R Shook; Noriko Shimasaki; Yu-Hsiang Chang; Hiroyuki Fujisaki; Dario Campana
Journal:  Clin Cancer Res       Date:  2010-06-11       Impact factor: 12.531

5.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

6.  Prospects for gene-engineered T cell immunotherapy for solid cancers.

Authors:  Christopher A Klebanoff; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

7.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

8.  Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.

Authors:  Tong Zhang; Amorette Barber; Charles L Sentman
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

9.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

10.  Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

Authors:  Maria Grazia Ruocco; Karsten A Pilones; Noriko Kawashima; Michael Cammer; Julie Huang; James S Babb; Mengling Liu; Silvia C Formenti; Michael L Dustin; Sandra Demaria
Journal:  J Clin Invest       Date:  2012-09-04       Impact factor: 14.808

View more
  28 in total

1.  Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.

Authors:  Lin Xiao; Dongzhi Cen; Haining Gan; Yan Sun; Nanqi Huang; Hanzhen Xiong; Qiongmei Jin; Liqun Su; Xuejuan Liu; Kejian Wang; Guangrong Yan; Tianfa Dong; Shangbiao Wu; Pengzhi Zhou; Jinshan Zhang; Weixiang Liang; Junlan Ren; Yaoshu Teng; Can Chen; Xue Hu Xu
Journal:  Mol Ther       Date:  2019-03-20       Impact factor: 11.454

2.  Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Authors:  Susanne H Baumeister; Joana Murad; Lillian Werner; Heather Daley; Helene Trebeden-Negre; Joanina K Gicobi; Adam Schmucker; Jake Reder; Charles L Sentman; David E Gilham; Frédéric F Lehmann; Ilene Galinsky; Heidi DiPietro; Kristen Cummings; Nikhil C Munshi; Richard M Stone; Donna S Neuberg; Robert Soiffer; Glenn Dranoff; Jerome Ritz; Sarah Nikiforow
Journal:  Cancer Immunol Res       Date:  2018-11-05       Impact factor: 11.151

3.  Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators.

Authors:  Mohit Sachdeva; Philippe Duchateau; Stéphane Depil; Laurent Poirot; Julien Valton
Journal:  J Biol Chem       Date:  2019-02-25       Impact factor: 5.157

Review 4.  Acute myeloid leukemia and NK cells: two warriors confront each other.

Authors:  Aroa Baragaño Raneros; Carlos López-Larrea; Beatriz Suárez-Álvarez
Journal:  Oncoimmunology       Date:  2018-10-31       Impact factor: 8.110

Review 5.  NKG2D and its ligands in cancer.

Authors:  Payal Dhar; Jennifer D Wu
Journal:  Curr Opin Immunol       Date:  2018-03-09       Impact factor: 7.486

Review 6.  CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?

Authors:  Thamizhselvi Ganapathy; Rajalingam Radhakrishnan; Seth Sakshi; Sunil Martin
Journal:  Cancer Immunol Immunother       Date:  2022-08-12       Impact factor: 6.630

7.  Toxicity Induced by a Bispecific T Cell-Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice.

Authors:  Claire Godbersen-Palmer; Tiffany A Coupet; Zakaria Grada; Samuel C Zhang; Charles L Sentman
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

Review 8.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

Review 9.  Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.

Authors:  Bruce R Blazar; Geoffrey R Hill; William J Murphy
Journal:  Nat Rev Clin Oncol       Date:  2020-04-20       Impact factor: 66.675

Review 10.  CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities.

Authors:  Joseph W Fischer; Nirjal Bhattarai
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.